Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting T...

Autores
Marin-Neto, José Antônio; Rassi, Anis; Morillo, Carlos A; Avezum, Álvaro; Connolly, Stuart J; Sosa-Estani, Sergio; Rosas, Fernando; Yusuf, Salim
Año de publicación
2008
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Marin-Neto, José Antônio. Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo; Brasil.
Fil: Rassi, Anis. Anis Rassi Hospital, Goiania; Brasil.
Fil: Morillo, Carlos A. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Fil: Avezum, Álvaro. Instituto Dante Pazzanese de Cardiologia, Sao Paulo; Brasil.
Fil: Connolly, Stuart J. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.
Fil: Rosas, Fernando. Clinica A. Saio, Bogota; Colombia.
Fil: Yusuf, Salim. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Benznidazole is effective for treating acute and chronic (recently acquired) Trypanosoma cruzi infection (Chagas' disease). Recent data indicate that parasite persistence plays a pivotal role in the pathogenesis of chronic Chagas' cardiomyopathy. However, the efficacy of trypanocidal therapy in preventing clinical complications in patients with preexisting cardiac disease is unknown.
Fuente
American Heart Journal 2008 Jul;156(1):37-43.
Materia
Cardiomiopatía Chagásica
Trypanosoma cruzi
Nivel de accesibilidad
acceso abierto
Condiciones de uso
none
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:123456789/1939
Acceder
id SGCANLIS_22325b3a44fc21add49c32c95943fed1
oai_identifier_str oai:sgc.anlis.gob.ar:123456789/1939
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)Marin-Neto, José AntônioRassi, AnisMorillo, Carlos AAvezum, ÁlvaroConnolly, Stuart JSosa-Estani, SergioRosas, FernandoYusuf, SalimCardiomiopatía ChagásicaTrypanosoma cruziFil: Marin-Neto, José Antônio. Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo; Brasil.Fil: Rassi, Anis. Anis Rassi Hospital, Goiania; Brasil.Fil: Morillo, Carlos A. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.Fil: Avezum, Álvaro. Instituto Dante Pazzanese de Cardiologia, Sao Paulo; Brasil.Fil: Connolly, Stuart J. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.Fil: Rosas, Fernando. Clinica A. Saio, Bogota; Colombia.Fil: Yusuf, Salim. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.Benznidazole is effective for treating acute and chronic (recently acquired) Trypanosoma cruzi infection (Chagas' disease). Recent data indicate that parasite persistence plays a pivotal role in the pathogenesis of chronic Chagas' cardiomyopathy. However, the efficacy of trypanocidal therapy in preventing clinical complications in patients with preexisting cardiac disease is unknown.Elsevier2008-07info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf0002-8703http://sgc.anlis.gob.ar/handle/123456789/193910.1016/j.ahj.2008.04.001American Heart Journal 2008 Jul;156(1):37-43.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISAmerican Heart Journalnoneinfo:eu-repo/semantics/openAccesseng2025-09-04T11:18:01Zoai:sgc.anlis.gob.ar:123456789/1939Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:18:01.492Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
title Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
spellingShingle Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
Marin-Neto, José Antônio
Cardiomiopatía Chagásica
Trypanosoma cruzi
title_short Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
title_full Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
title_fullStr Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
title_full_unstemmed Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
title_sort Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)
dc.creator.none.fl_str_mv Marin-Neto, José Antônio
Rassi, Anis
Morillo, Carlos A
Avezum, Álvaro
Connolly, Stuart J
Sosa-Estani, Sergio
Rosas, Fernando
Yusuf, Salim
author Marin-Neto, José Antônio
author_facet Marin-Neto, José Antônio
Rassi, Anis
Morillo, Carlos A
Avezum, Álvaro
Connolly, Stuart J
Sosa-Estani, Sergio
Rosas, Fernando
Yusuf, Salim
author_role author
author2 Rassi, Anis
Morillo, Carlos A
Avezum, Álvaro
Connolly, Stuart J
Sosa-Estani, Sergio
Rosas, Fernando
Yusuf, Salim
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cardiomiopatía Chagásica
Trypanosoma cruzi
topic Cardiomiopatía Chagásica
Trypanosoma cruzi
dc.description.none.fl_txt_mv Fil: Marin-Neto, José Antônio. Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo; Brasil.
Fil: Rassi, Anis. Anis Rassi Hospital, Goiania; Brasil.
Fil: Morillo, Carlos A. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Fil: Avezum, Álvaro. Instituto Dante Pazzanese de Cardiologia, Sao Paulo; Brasil.
Fil: Connolly, Stuart J. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.
Fil: Rosas, Fernando. Clinica A. Saio, Bogota; Colombia.
Fil: Yusuf, Salim. McMaster University, Population Health Research Institute HGH-McMaster Clinic, East Hamilton, Ontario; Canada.
Benznidazole is effective for treating acute and chronic (recently acquired) Trypanosoma cruzi infection (Chagas' disease). Recent data indicate that parasite persistence plays a pivotal role in the pathogenesis of chronic Chagas' cardiomyopathy. However, the efficacy of trypanocidal therapy in preventing clinical complications in patients with preexisting cardiac disease is unknown.
description Fil: Marin-Neto, José Antônio. Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo; Brasil.
publishDate 2008
dc.date.none.fl_str_mv 2008-07
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 0002-8703
http://sgc.anlis.gob.ar/handle/123456789/1939
10.1016/j.ahj.2008.04.001
identifier_str_mv 0002-8703
10.1016/j.ahj.2008.04.001
url http://sgc.anlis.gob.ar/handle/123456789/1939
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv American Heart Journal
dc.rights.none.fl_str_mv none
info:eu-repo/semantics/openAccess
rights_invalid_str_mv none
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv American Heart Journal 2008 Jul;156(1):37-43.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1842344422994345984
score 12.623145

Publicaciones similares